Keytruda to become best-selling drug globallyOn Friday, financial Cinco Días carried a story that forecasts that Merck & Co's Keytruda (pembrolizumab) will take over AbbVie’s Humira (adalimumab) at the top of the list of biggest selling drugs.
Paediatrician disbarred for spreading arguments against vaccinationA paediatrician working in Madrid has been disbarred following reports of her telling patients and writing articles against vaccination, dailies El País, El Diario, 20 Minutos and Público report on Friday.
Difficulties in access to epilepsy drugsOn Friday, daily El País reports that three out of five epilepsy patients lack access to proper treatments, even those which are sold at less than €5.
Tranquilisers used as recreational drugs by Spanish youngstersOn Thursday, daily El Mundo carried a lengthy story on the so-called "Lexatin generation", about increased abuse of benzodiazepine bromazepam and other tranquilisers among Spanish adolescents and young adults.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.